Original research

Influence of peroxisome proliferator-activated receptor-γ exon 2 and exon 6 and insulin receptor substrate (IRS)-1 Gly972Arg polymorphisms on insulin resistance and beta-cell function in southern Mediterranean women with polycystic ovary syndrome

Annalisa Giandalia, Maria Angela Pappalardo, Giuseppina T. Russo, Elisabetta L. Romeo, Angela Alibrandi, Flavia Di Bari, Roberto Vita, Domenico Cucinotta, Salvatore Benveniga

A B S T R A C T

Background and objective: The Pro12Ala (exon 2) and His447His (exon 6) polymorphisms of PPAR-γ and Gly972Arg polymorphism of IRS-1 have been implicated in insulin resistance (IR) and adiposity. Our aim was to investigate the influence of these polymorphisms on metabolic features of polycystic ovary syndrome (PCOS).

Methods: Fifty-three PCOS women and 26 control women underwent a clinical and biochemical evaluation, including a 75-g oral glucose tolerance test. Insulin secretion and insulin sensitivity indices were calculated.

Results: Frequencies of PPAR-γ polymorphisms did not differ from those predicted by the Hardy-Weinberg equilibrium. Instead, the IRS-1 Gly972Arg allele was significantly more frequent in the PCOS group compared to controls. The most frequent allelic combinations were IRS1+/exon2-/exon6- (which prevailed in PCOS) and IRS1-/exon2-/exon6- (which prevailed in controls). Among PCOS women, compared with the wild type patients, carriers of the Gly972Arg IRS-1 allele had lower E2 levels, while carriers of the Pro12Ala PPAR-γ (exon 2) allele had lower free testosterone levels. No other significant relationships were noted. When compared with the wild type, in PCOS group IR and beta-cell function were: (i) trendwise greater in carriers of the variant IRS-1 allele; (ii) trendwise lower in carriers of the variant PPAR-γ exon 2 allele; (iii) significantly lower in carriers of the variant PPAR-γ exon 2 allele.

Conclusions: Our data support the protective influence of PPAR-γ exon 2 and exon 6 variants on IR and beta-cell function, whereas IRS-1 polymorphism is associated with an unfavorable metabolic profile. However, these associations do not fully explain the high metabolic risk associated with PCOS.

Introduction

PCOS is one of the most common endocrinopathies, as it affects 5–10% of the female population in the reproductive age [1]. In addition to the variable combinations of hirsutism, menstrual cycle irregularities and ultrasonographic ovarian abnormalities, PCOS is characterized by an insulin resistance-associated metabolic derangement [2]. Thus, among PCOS women, the rate of metabolic syndrome is up to 46%, the rate of obesity is over 50%, and the risk of type 2 diabetes mellitus is approximately 7-fold greater compared with non-PCOS women [2].

Insulin resistance has been implicated in the pathogenesis of PCOS [3]. Insulin resistance leads to the development of metabolic syndrome and independently increases the cardiovascular risk [3]. Therefore, the AE-PCOS Society has advised to assess the cardiovascular risk in all...
PCOS women [4]. Particularly, AE-PCOS suggested to evaluate the lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides) and the carbohydrate metabolism (a 2-h 75 g glucose challenge) at least every two years [4].

Although insulin resistance is related to obesity, PCOS women are insulin resistant independently of body mass index (BMI). Indeed, about half of them are resistant to insulin irrespective of ethnicity [5]. Hyperinsulinemia ensues in order to override the reduced peripheral insulin sensitivity. Only in PCOS women, but not in other hyperinsulinemic states (e.g. type 2 diabetes mellitus) hyperinsulinemia increases the ovarian and adrenal androgen production and androgen bioavailability by reducing circulating levels of SHBG [6]. This insulin-related hyperandrogenism implies that: i) insulin-sensitizing agents ameliorate hyperandrogenism [7]; ii) beta-cell dysfunction can be used as an independent predictor of hyperandrogenemia [8].

PCOS and insulin resistance share a common genetic background, as a number of polymorphisms of genes involved in insulin resistance were found in PCOS women. The most common polymorphisms are those involved in insulin signaling, such as insulin gene [9] and genes encoding the IRS [10,11]. For instance, the Gly972Arg variant of IRS-1 gene has been associated to insulin resistance, type 2 diabetes, and PCOS [10]. We have found a significantly greater prevalence of this variant in PCOS women compared with controls [10,11]. A probable role in PCOS pathogenesis can be played by the calpain 10 gene polymorphisms [12] and the PPAR-γ polymorphisms [13].

However, studies exploring the association with PCOS of either one of the two single-nucleotide polymorphisms of the PPAR-γ gene, viz. Pro12Ala (C/G replacement in exon 2) and His447His (C/T replacement in exon 6), have yielded contradictory results [14-16].

PCOS is a multifactorial disorder in which various gene-gene or gene-environment interactions may influence the pleomorphic phenotype, including the metabolic profile. Hence, in the present study we have evaluated i) the prevalence of the two aforementioned PPAR-γ variants (Pro12Ala and His447His) and the Gly972Arg IRS-1 variant, and their relative combinations; ii) the influence of these polymorphisms on phenotype, with respect to hyperandrogenism, insulin resistance and beta-cell function.

Materials and methods

Study subjects

Fifty-three consecutive Caucasian women with PCOS attending the Endocrine outpatient clinic of the Department of Clinical and Experimental Medicine at our University hospital were recruited. All women were born and stably resident in the two southernmost regions of Italy, namely Sicily and Calabria. PCOS was diagnosed according to the Rotterdam criteria [1]. Women were excluded if they: i) had hyperandrogenic conditions other than PCOS (such as non-classical congenital adrenal hyperplasia, Cushings syndrome, and androgen-secreting tumors); ii) had either type 1 or type 2 diabetes mellitus; iii) had either hypothryoidism or hyperthyroidism; iv) had been treated with contraceptive pills for the previous 6 months; v) had been treated with insulin-sensitizers (including metformin and inositol) for the previous 6 months. Twenty-six age-matched healthy women including nurses, medical students and young clinicians, were recruited as controls. They had neither PCOS nor other conditions mentioned above in the exclusion criteria. All participants gave their informed consent before entering the study, which was approved by the Internal Review Board.

Methods

Clinical evaluation

Participants underwent a complete physical examination, including assessment of weight, height, BMI, and Ferriman-Gallwey score.

Basal biochemical measurements

Women underwent a fasting blood sampling in the morning (7:30–8:30 a.m.) between the second and the seventh day of the menstrual cycle. Metabolic parameters (plasma glucose, insulin, total cholesterol, HDL-cholesterol and triglycerides levels), SHBG, and hormonal parameters (FSH, LH, total testosterone, free testosterone, calculated free testosterone [using the formula available at http://issam.ch/freetesto.html], E2, Δ4-androstenedione, 17-OHP) were evaluated.

Indices of insulin-resistance and β-cell function

A 2-h 75 g OGTT with blood sampling for glucose and insulin at baseline (time 0), 30, 60, 90 and 120 min was performed. Insulin resistance was evaluated by using the HOMA-IR and the Matsuda index (also known as insulin sensitivity index). HOMA-IR was calculated with the following formula: [glycemia at 0 min (mg/dl) × insulin at 0 min (μU/ml)]/405. Matsuda index was calculated with the formula: (10,000/√[(glycemia at 0 min (mg/dl) × insulin at 0 min (μU/ml)) × (glycemia during OGTT × mean insulin during OGTT)].

β-cell function was evaluated by using the IGI with the formula [(insulin at 30 min) – (insulin at 0 min)]/(glycemia at 30 min) – (glycemia at 0 min)]. We also calculated the DI, a composite measure of β-cell function. DI is calculated multiplying IGI by the Matsuda index.

Genetic analysis

Genomic DNA was extracted from peripheral blood mononuclear cells using the QIAamp DNA blood Mini Kit (Qiagen, Venlo, The Netherlands) according to the manufacturer’s recommended protocol. Gene polymorphisms were analyzed by PCR and restriction fragment length polymorphism.

IRS-1 polymorphism was genotyped as previously described [10]. Briefly, a 198 bp DNA sequence was amplified by PCR using oligonucleotide primers 5’-CTTTCACAGCTGACCTC-3’ (forward) and 5’-GTTAGGCTGCAAATGCT-3’ (reverse). PCR products were digested with 2 μL of the restriction enzyme SmaI (BioLabs, New England, USA) and the fragments were separated by 1.5% agarose gel electrophoresis and visualized by UV illumination, after ethidium bromide staining. Genotype was indicated by the size of the resolved fragments: homozygosity (Arg972Arg on both alleles) by the undigested 198 bp fragment, heterozygosity (Gly972Gly on one allele and the variant Gly972Arg on the other allele) by the undigested 198 bp fragment plus the 171 bp and 27 bp fragments resulting from digestion, and wild-type (Gly-972Gly on both alleles) by the absence of the 198 band and the absence of the fragments (that is, the 171 bp and the 27 bp bands).

PPAR-γ gene polymorphisms in exon 2 (C/G transversion, resulting in Pro12Ala at protein level) and exon 6 (the silent C/T transition, resulting in maintenance of His at residue 447 of the protein) were analyzed by Orio et al. [17]. Briefly, PPAR-γ exon-2 poly-morphism sequence was amplified by PCR using these primers: 5’-CTGATGTCTTGACTCATGGG-3’ (forward) and 5’-GGAAAGAACAATCAGGACGC-3’ (reverse). The PCR product of 295 bp was digested using PmlI. The wild type CC genotype was identified by the undigested products 142 bp and 39 bp fragments, whereas the variant T allele was identified by the 171 bp and 27 bp fragments. Regardless of the polymorphism investigated, PCR products and digestion products were separated on 3% agarose gel electrophoresis and visualized under UV light after ethidium bromide staining of the gel.
Statistical analysis

Statistical analyses were performed using SPSS version 11.0 (Statistical Package for the Social Sciences, Chicago, IL, USA) for Windows. Numerical data are given as m ± SD and categorical variables as number and percentage.

Since the majority of the examined variables were distributed normally, as verified by the Kolmogorov-Smirnov test, parametric tests were used. Differences between m ± SD of continuous variables were addressed by the two-tailed Student’s t-test, while differences between proportions of categorical variables by the \( \chi^2 \) test or the Fisher’s exact test, as appropriate.

Partial correlation coefficients between E2 levels and all study variables were analyzed, controlling for BMI. A formal test for interaction between IRS-1 genotype and E2 levels on metabolic parameters was performed to determine whether E2 levels modified the association between genotype and study variables. Finally, the possible dependence of IRS-1*E2 PPAR-γ exon 2*E2 PPAR-γ exon 6*E2 on each of the examined variables was estimated by univariate linear regression models, both in the PCOS group and in the control group.

All statistical comparisons were two-tailed, and a P value < 0.05 was considered statistically significant; a P value comprised between 0.05 and 0.10 was considered borderline significant.

**Results**

**Clinical characteristics of women with PCOS**

Table 1 summarizes the relevant characteristics of the 53 PCOS women and the 26 controls. As expected, PCOS women were heavier, had worse clinical hirsutism, higher biochemical androgen levels and worse metabolic profile (i.e. greater fasting insulin and HOMA-IR, greater triglycerides and lower HDL-cholesterol levels).

| PCOS group | Control group |
|------------|---------------|
| n          | 53            | 26            |
| Age (years)| 22.85 ± 5.30  | 25.00 ± 5.55  |
| BMI (kg/m²)| 29.13 ± 8.32  | 24.92 ± 4.57  |

| Hormonal profile             | PCOS group | Control group |
|------------------------------|------------|---------------|
| Ferriman Score               | 11.74 ± 4.61 | 8.38 ± 3.11   |
| LH (mIU/ml)                  | 7.71 ± 5.27  | 7.20 ± 4.64   |
| 17β-estradiol (pg/ml)        | 45.52 ± 21.20 | 42.82 ± 17.12 |
| 17-OHPg (ng/ml)              | 1.31 ± 0.51  | 1.03 ± 0.46   |
| SHBG (nmol/l)                | 37.98 ± 21.81 | 41.68 ± 18.28 |
| Δ4AAND (ng/ml)               | 2.38 ± 1.23  | 2.30 ± 1.40   |
| Total testosterone (ng/dl)   | 69.41 ± 28.79 | 54.19 ± 21.45 |
| Calculated free testosterone (pg/ml) | 1.30 ± 0.83 | 0.94 ± 0.47   |
| Metabolic parameters         |            |               |
| Fasting plasma glucose (mg/dL)| 76.79 ± 9.46 | 82.38 ± 13.24 |
| Fasting insulin (mU/L)       | 12.87 ± 9.03 | 7.74 ± 4.70   |
| HOMA-IR                      | 2.48 ± 1.88  | 1.45 ± 1.00   |
| Matsuda index                | 5.11 ± 3.39  | 5.14 ± 3.10   |
| Insulin resistance           |            |               |
| Insulinogenic index          | 1.90 ± 2.57  | 2.16 ± 1.30   |
| Disposition index            | 7.57 ± 8.80  | 10.36 ± 7.67  |
| Lipid Profile                |            |               |
| Total cholesterol (mg/dl)    | 173.20 ± 41.09 | 193.54 ± 35.74 |
| HDL cholesterol (mg/dl)      | 56.14 ± 12.81 | 66.44 ± 11.08 |
| Triglycerides (mg/dl)        | 80.94 ± 42.43 | 68.85 ± 21.76 |

* The exon 6 polymorphism of PPAR-γ is a silent one, in that the C to T nucleotide substitution does not change the amino acid encoded.

**PCOS group**

| Genotype distribution | PCOS group | Control group |
|-----------------------|------------|---------------|
| TT                    | 8 (15.1%)  | 22 (84.6%)    |
| TA                    | 44 (83.0%) | 4 (15.4%)     |
| AA                    | 1 (1.9%)   | < 0.0001     |
| A-carriers            | 45 (84.9%) | 4 (15.4%)     |
| G-carriers            | 3 (5.7%)   | 4 (15.4%)     |
| PPAR-γ exon6          |            |               |
| TC                    | 50 (94.3%) | 22 (84.6%)    |
| CC                    | 3 (5.7%)   | 4 (15.4%)     |
| GO                    | 0          | 0             |
| GG                    | 0          | 0             |
| C-carriers            | 3 (5.7%)   | 4 (15.4%)     |
| PPAR-γ exon6 His447His | 41 (77.4%) | 24 (92.3%)    |
| CT                    | 11 (20.7%) | 2 (7.7%)      |
| TT                    | 1 (1.9%)   | 0             |
| G-carriers            | 3 (5.7%)   | 4 (15.4%)     |
| T-carriers            | 12 (22.6%) | 2 (7.7%)      |

Because mutations in homozygosity were detected only in two PCOS women (one for the AA alleles of IRS-1, and one for the TT alleles of exon 6 of PPAR-γ), these variants were pooled with the corresponding heterozygous alleles for description and statistics. Data are summarized in Table 2.

PCOS women showed a significantly higher frequency of the Gly972Arg and Arg972Arg combined genotypes of IRS-1 as compared to control women (84.9% vs. 15.4%, \( P < 0.0001 \)). In terms of allele frequency, the rates of the A allele in the two groups of women were 45/106 (42.4%) vs. 4/52 (7.7%, \( P < 0.0001; \) OR = 8.8, 95% CI = 3.0–26.3). The allelic distribution of the IRS-1 genotypes was in Hardy-Weinberg equilibrium in the control group, but not in the PCOS group.

Conversely, both PPAR-γ exon 2 and exon 6 polymorphisms frequencies did not differ from those predicted from the Hardy-Weinberg equilibrium both in PCOS women and in controls. The frequency of the PPAR-γ exon-2 rare G allele was 5.7% and 15.4% in control women (\( P = 0.21; \) OR = 0.33, 95% CI = 0.07–1.6), and that of the PPAR-γ exon-6 rare T allele 20.7% in PCOS women and 7.7% in control women (\( P = 0.20; \) OR = 3.2, 95% CI = 0.75–15.8). In brief, in the PCOS group compared to the control group, the IRS-1 A allele and the PPAR-γ exon-6 T allele were overrepresented, while the PPARγ exon-2 G allele was under-represented.

The bottom part of Table 2 shows the possible genetic combinations, and how they associate with the presence or absence of PCOS. Particularly evident is the risk for PCOS associated with the heterozygous/homozygous presence of A at codon 972 of the IRS-1 gene, and the protection associated with the heterozygous/homozygous presence of G at codon 12 and T at codon 447 of the PPAR-γ gene. Of 24 women (PCOS + controls) who were wild type for all three codons (and therefore were homozygous carriers of G, C and C at codons 972 of IRS-156806).
γ polymorphism (PPAR-

significantly concerning E2 levels. In PCOS women, significant interactions were noted for IRS-1 polymorphism (Table 2).

Table 3 summarizes the clinical, hormonal and metabolic parameters in PCOS women as a whole, and PCOS women stratified dichotomically (wild type vs. heterozygous/homozygous carriers of the variant) for each polymorphism disregarding the status for the other two polymorphisms. Taking into account the unequal size of any two strata, only two comparisons yielded a statistically significant difference: E2 levels (IRS-1 polymorphism) and measured free testosterone levels (PPAR-γ exon 2 polymorphism). Because of only three carriers of the exon 2 variant of PPAR-γ, no inferences can be drawn from the presence/absence of this polymorphism per se, disregarding the other two polymorphisms studied here. We explored further the association concerning E2 levels. In PCOS women, significant interactions were noted for IRS-1 polymorphism (IRS-1+/E2) with DI (P for interaction = 0.048). Significant interactions were also noted for PPAR-γ exon 2 polymorphism (PPAR-γ exon 2+E2) with fasting insulin levels (P = 0.026) and HOMA-IR (P = 0.001), and trend wise interaction for PPAR-γ exon 6 polymorphism (PPAR-γ exon 6+E2) with fasting insulin levels (P = 0.052).

Carriers of the IRS-1 polymorphisms had greater serum levels of fasting insulin (+16.9%), and triglycerides (+21.4%) compared to the wild types. The worse glycometabolic status of the IRS-1 variant carriers compared to noncarriers (wild types) can be appreciated by the greater HOMA-IR (+17.1%), greater compensatory insulin secretion, and greater both DI (+41.0%) and IGI (+28.9%) (Table 3).

In sharp contrast, carriers of the PPAR-γ exon 6 variant had lower levels of fasting insulin (−36.3%) and triglycerides (−26.3%) compared to noncarriers. The better glycometabolic status of the PPAR-γ exon 6 variant carriers compared to noncarriers is reflected by lower fasting insulin (−36.3%), lower HOMA-IR (−36.2%), lower DI and IGI (−32.7% and −42.7%), and greater Matsuda index (+50.6%). In turn, carriers of the PPAR-γ exon 6 variant had lower levels of fasting insulin (−32.1%), triglycerides (−23.8%), HOMA-IR (−33.2%), DI (−36.2%) and IGI (−39.0%) compared to carriers of the IRS-1 variant (Table 3).

However, exon 6 PPAR-γ wild type PCOS women had greater levels of fasting insulin (+24.5%) and triglycerides (+25.5%), greater insulin resistance (HOMA-IR, +25%), greater DI (+40.8%) and greater IGI (+43.4%) compared to the IRS-1 wild type PCOS women. A similar trend, but more attenuated for the carbohydrate metabolism was true for the comparison between the 50 PCOS noncarriers of the PPAR-γ exon 2 variant and the 8 PCOS women noncarriers of the IRS-1 variant (fasting insulin, +14.8%; triglycerides, +19.0%; HOMA-IR, +14.3%; DI, +24.4%; IGI, +5.3%).

Hormonal and metabolic parameters based on combinations of IRS-1, PPAR-γ exon 2 and exon 6 polymorphisms in women with PCOS

Omitting the combination groups with 2 or fewer women, Table 4 confirms what shown in Table 3 for the most favorable glycometabolic profile in carriers of the PPAR-γ exon 6 variant. The benefit associated with the IRS-1+/PPAR-γ exon 2−/PPAR-γ exon 6+ combination is amplified by the lowest BMI, lowest triglycerides and highest HDL cholesterol. Furthermore, confirming data in Table 3, this combination was associated with the lowest E2 levels. Because the 8 women with this combination also had the highest levels of free testosterone, this could explain why they had the greatest degree of hirsutism (i.e. greatest Ferriman-Gallwey score) (Table 4).
A. Giandalia et al.  
Journal of Clinical & Translational Endocrinology 13 (2018) 1–8

and PPAR-γ variant is equally distributed between the two BMI categories, the two disposition index. For this purpose, only groups of 5 or more women were wished to assess whether any single polymorphism was more likely to occur in PCOS women with ideal weight (BMI < 25 kg/m²). Because of the frequent presence of overweight/obesity in PCOS women, we wished to assess whether any single polymorphism was associated with BMI and leptin levels [13]. Indeed, each of three polymorphisms (Gly972Arg of IRS-1 gene, Pro12Ala [exon 2] and His447His [exon 6] of PPAR-γ gene) have been associated with PCOS and variably with its metabolic aspects [10,11,13–16].

In this regard, we have recently reported a higher frequency of IRS-1 Gly972Arg variant in PCOS women compared to controls, and a more unfavorable metabolic profile in carriers of this polymorphism [10,11] (Supplementary Tables 1 and 2).

In the present study, we explored whether exon 2 and exon 6 PPAR-γ variants may contribute, alone or in combination with IRS-1 polymorphism, to the metabolic derangements observed in PCOS women (Table 6).

Consistently with our previous works [10,11] we have confirmed the higher frequency of the IRS-1 gene variant among our PCOS women compared with controls, in contrast with the PPAR-γ exon 2 and exon 6 variants whose frequencies were comparable in the two groups and did not differ from the frequencies predicted by the Hardy-Weinberg equilibrium. In this regard, in Italian [17,18], Spanish [19], Greek [15,20,21], German [22], Polish [23], Chinese [24], Turkish [25], and Korean women [14] PCOS women the PPAR-γ exon 2 variant has been reported as frequent as in controls. In contrast with these studies, others reported an increased frequency of PPAR-γ exon 2 variant in nonPCOS women, suggesting a protective effect of this polymorphism [26–28]. Also, in contrast with Europeans PCOS women, in non European ones this effect was not found [29]. Particularly, one study [17] found that the Pro12Ala variant in PPAR-γ exon 2 does not influence BMI, as opposed to other studies [13,20].

A few studies have examined concurrently both PPAR-γ exon 2 and exon 6 polymorphisms [15,17,27,30]. One of these studies [30] on a large cohort found no difference in the genotype frequencies between PCOS and controls and lower testosterone levels and milder insulin resistance in controls that carried the PPAR-γ exon 2 variant. In another study, Christopoulos reported higher frequency of IRS-1 gene variant among our PCOS women compared with controls, in contrast with the PPAR-γ exon 2 variant. In another study, Christopoulos reported a higher frequency of IRS-1 gene variant among our PCOS women compared with controls. In contrast with the PPAR-γ exon 2 and exon 6 variants whose frequencies were comparable in the two groups and did not differ from the frequencies predicted by the Hardy-Weinberg equilibrium. In this regard, in Italian [17,18], Spanish [19], Greek [15,20,21], German [22], Polish [23], Chinese [24], Turkish [25], and Korean women [14] PCOS women the PPAR-γ exon 2 variant has been reported as frequent as in controls. In contrast with these studies, others reported an increased frequency of PPAR-γ exon 2 variant in nonPCOS women, suggesting a protective effect of this polymorphism [26–28]. Also, in contrast with Europeans PCOS women, in non European ones this effect was not found [29]. Particularly, one study [17] found that the Pro12Ala variant in PPAR-γ exon 2 does not influence BMI, as opposed to other studies [13,20].

A few studies have examined concurrently both PPAR-γ exon 2 and exon 6 polymorphisms [15,17,27,30]. One of these studies [30] on a large cohort found no difference in the genotype frequencies between PCOS and controls and lower testosterone levels and milder insulin resistance in controls that carried the PPAR-γ exon 2 variant. In another study, Christopoulos reported higher frequency of IRS-1 gene variant among our PCOS women compared with controls. In contrast with the PPAR-γ exon 2 variant. In another study, Christopoulos reported a higher frequency of IRS-1 gene variant among our PCOS women compared with controls. In contrast with the PPAR-γ exon 2 and exon 6 variants whose frequencies were comparable in the two groups and did not differ from the frequencies predicted by the Hardy-Weinberg equilibrium. In this regard, in Italian [17,18], Spanish [19], Greek [15,20,21], German [22], Polish [23], Chinese [24], Turkish [25], and Korean women [14] PCOS women the PPAR-γ exon 2 variant has been reported as frequent as in controls. In contrast with these studies, others reported an increased frequency of PPAR-γ exon 2 variant in nonPCOS women, suggesting a protective effect of this polymorphism [26–28]. Also, in contrast with Europeans PCOS women, in non European ones this effect was not found [29]. Particularly, one study [17] found that the Pro12Ala variant in PPAR-γ exon 2 does not influence BMI, as opposed to other studies [13,20].

A few studies have examined concurrently both PPAR-γ exon 2 and exon 6 polymorphisms [15,17,27,30]. One of these studies [30] on a large cohort found no difference in the genotype frequencies between PCOS and controls and lower testosterone levels and milder insulin resistance in controls that carried the PPAR-γ exon 2 variant. In another study, Christopoulos reported lower testosterone levels in PCOS compared with controls, in contrast with the PPAR-γ exon 2 and exon 6 variants whose frequencies were comparable in the two groups and did not differ from the frequencies predicted by the Hardy-Weinberg equilibrium. In this regard, in Italian [17,18], Spanish [19], Greek [15,20,21], German [22], Polish [23], Chinese [24], Turkish [25], and Korean women [14] PCOS women the PPAR-γ exon 2 variant has been reported as frequent as in controls. In contrast with these studies, others reported an increased frequency of PPAR-γ exon 2 variant in nonPCOS women, suggesting a protective effect of this polymorphism [26–28]. Also, in contrast with Europeans PCOS women, in non European ones this effect was not found [29]. Particularly, one study [17] found that the Pro12Ala variant in PPAR-γ exon 2 does not influence BMI, as opposed to other studies [13,20].

A few studies have examined concurrently both PPAR-γ exon 2 and exon 6 polymorphisms [15,17,27,30]. One of these studies [30] on a large cohort found no difference in the genotype frequencies between PCOS and controls and lower testosterone levels and milder insulin resistance in controls that carried the PPAR-γ exon 2 variant. In another study, Christopoulos reported lower testosterone levels in PCOS carriers of the PPAR-γ exon 6 variant [15].

Only three studies have investigated the relationship between the silent polymorphism His447His of PPAR-γ exon 6 in PCOS with different conclusions. For instance, Antoine et al. [30] have found that this variant did not increase the risk of developing PCOS and was not associated with insulin-related traits or androgen levels in women with PCOS, but instead, they demonstrated that controls carrying the His447His allele had improved insulin sensitivity and decreased mean levels of free and total testosterone. Another study carried out on an Italian cohort of PCOS women [17] reported a significant increase in T allele frequency but not an association of this allele with circulating androgens. Furthermore this variant influences BMI and leptin levels [17].

In our population the different allelic combinations were unequally distributed among PCOS and controls, the most frequent being the IRS1+/E6/-E2- combination, which regarded two-thirds of PCOS

Table 4
Clinical, hormonal and metabolic parameters in PCOS women according to BMI. NS = not significant (P > 0.10).

| N | BMI (kg/m²) | Age (years) | PPAR-G exon 2 | PPAR-γ exon 6 |
|---|---|---|---|---|
| 19 | 21.68 ± 1.92 | 23.74 ± 6.31 | NS | NS |
| 34 | 33.29 ± 7.56 | 22.35 ± 4.68 | NS | NS |

Table 5
Clinical, hormonal and metabolic parameters in PCOS women according to BMI. NS = not significant (P > 0.10).

| N | BMI (kg/m²) | Age (years) | Genotype | P | PPAR-γ wt | PPAR-γ carrier |
|---|---|---|---|---|---|---|
| 19 | 21.68 ± 1.92 | 23.74 ± 6.31 | NS | NS | NS | NS |
| 34 | 33.29 ± 7.56 | 22.35 ± 4.68 | NS | NS | NS | NS |

Table 6
Clinical, hormonal and metabolic parameters in PCOS women according to BMI. NS = not significant (P > 0.10).

| N | BMI (kg/m²) | Age (years) | Genotype | P | PPAR-γ wt | PPAR-γ carrier |
|---|---|---|---|---|---|---|
| 19 | 21.68 ± 1.92 | 23.74 ± 6.31 | NS | NS | NS | NS |
| 34 | 33.29 ± 7.56 | 22.35 ± 4.68 | NS | NS | NS | NS |

Discussion
PCOS is a polygenic, multifaceted disease with a frequent metabolic component (overweight/obesity, increased serum levels of triglycerides, fasting insulin and decreased insulin sensitivity) [2]. Among the various possible phenotypes resulting from combinations of clinical, endocrine and metabolic abnormalities, the final phenotype will depend from the interaction of the environment with the genetic background. As mentioned in the section “Introduction”. Introduction, IRS-1 and PPAR-γ have emerged as significant candidate genes in the pathogenesis of PCOS. IRS-1 gene encodes the substrate of insulin receptor, which is crucial in insulin signaling [10]. PPAR-γ gene is involved in adipocyte differentiation, glucose and lipid metabolism [13]. Indeed, each of three polymorphisms (Gly972Arg of IRS-1 gene, Pro12Ala [exon 2] and His447His [exon 6] of PPAR-γ gene) have been associated with PCOS and variably with its metabolic aspects [10,11,13–16].
Table 6
Summary of the literature on the PPAR-\(\gamma\) exon 2 (Pro12Ala) and PPAR-\(\gamma\) exon 6 (His447His) polymorphisms.

| PPAR\(\gamma\) exon 2 | Country                  | PCOS criteria          | No of women | Polymorphism (Pro12Ala + Ala/Ala) | Comments |
|----------------------|--------------------------|------------------------|-------------|-----------------------------------|----------|
| First author [Ref.]  |                          | Controls PCOS          | Controls PCOS |                                   |          |
| Russo, this study    | Italy (south)            | Rotterdam              | 26          | 53                                | 15.4%    | 5.7%  |
| Orio Jr [17]         | Italy                    | NIH                    | 100         | 100                               | 9%       | 7%    |
| Orio Jr. [18]        | Italy                    | NIH                    | 120         | 120                               | 4.2%     | 5.9%  |
| Korhonen [26]        | Finland                  | Anovulation and PCO    | 115         | 135                               | 19.1%    | 12.6% |
| Hahn [13]            | Germany                  | NIH                    | 104         | 102                               | 23.1%    | 22.9% |
| Xita [21]            | Greece                   | NIH                    | 140         | 180                               | 6.8%     | 9.7%  |
| Koika [20]            | Greece                   | NIH                    | 56          | 156                               | 14.3%    | 12.3% |
| San Millan [19]      | Spain                    | NIH                    | 42          | 72                                | 21.4%    | 10%   |
| Christopolous [15]   | Greece                   | Rotterdam              | 148         | 183                               | 6.5%     | 5.5%  |
| Bidzinska-Speichert [23] | Poland                | Rotterdam              | 51          | 54                                | 26.5%    | 23.1% |
| Antoine [30]         | USA (white women)        | NIH                    | 187         | 285                               | 20.2%    | 20.2% |
| Yilmaz [27]          | Turkey                   | Rotterdam              | 100         | 100                               | 22%      | 15%   |
| Tok [25]             | Turkey                   | Hyperandrogenism, oligomenorrhea, PCO | 60 | 60                               | 21.7%    | 10%   |
| Dasgupta [16]        | India                    | Rotterdam              | 299         | 250                               | 16%      | 11%   |
| Shaikh [28]          | India                    | Rotterdam              | 300         | 450                               | 27%      | 15.3% |
| Wang [24]            | China                    | Rotterdam              | 147         | 201                               | 6.5%     | 9%    |
| Chae [14]            | South Korea              | Rotterdam              | 256         | 184                               | 10.1%    | 7.1%  |

This polymorphism was as frequent in PCOS women as in controls. Carriers of the polymorphism had lower free testosterone levels compared with wild types.

The frequency of the G allele of exon 2 was similar in PCOS and controls. BMI, leptin levels and leptin to BMI ratio did not differ significantly between or within both groups.

The frequency of this variant was significantly reduced in PCOS women. Also, genotype distributions of this variant were different with borderline significance between PCOS and controls.

The Pro12Ala polymorphism was as frequent in PCOS women as in controls. This polymorphism did not differ in PCOS and controls. Controls who carried the Ala allele had trendwise lower levels of total testosterone compared with noncarriers. This polymorphism was not influence the risk of developing PCOS or their phenotypic traits.

The frequency of this variant did not differ in PCOS and controls. Controls who carried the Ala allele had trendwise lower levels of total testosterone compared with noncarriers. This polymorphism was not influence the risk of developing PCOS or their phenotypic traits.

The Pro12Ala polymorphism, which was heterozygous in all women analyzed, was significantly more common in controls than in PCOS women. Both PCOS and controls who carried the Ala allele had lower levels of androgens, lower insulin, HOMA-IR, AUC_insulin and waist-to-hip ratio, compared with the Pro allele carriers. Also, PCOS carriers of this variant had lower Ferriman-Gallwey and acne scores compared with the wild types.

The frequency of this polymorphism did not differ in PCOS women and in controls. In both groups, no woman was heterozygous. Carriers of this variant were less insulin resistant and less glucose intolerant, as demonstrated by 2-h glucose concentrations.

Departure from expected Hardy-Weinberg proportions was observed. Haplotype association analysis revealed reduced frequency of hyperandrogenic and metabolic traits associated with PPAR-\(\gamma\) haplotypes. Pro12Ala was more frequent in PCOS women compared with controls.

Carriers of this variant had significantly reduced 2-h glucose levels compared with wild type women.

There was no statistical difference in genotype distribution, in BMI and hormone levels between PCOS and controls.

Genotype distribution was compatible with the expected Hardy-Weinberg equilibrium. Biochemical and clinical parameters of hyperandrogenism, indices of glucose tolerance and insulin resistance did not differ according to the genotype both in PCOS women and in controls. However, among PCOS women, HDL cholesterol levels were significantly higher in non-Pro/Pro women compared with Pro/Pro women.

(continued on next page)
women and the IRS1-/E6-/E2-, which regard three-fourths of controls. The only study in literature that analyzed concomitantly these three polymorphisms, was an Indian study [16], in which the authors found different haplotype distribution between PCOS and control women, although the combinations explored were different from those in our analysis. Particularly, while the IRS-1 polymorphism was represented similarly in cases and controls, the PPAR-γ exon 2 and exon 6 polymorphisms were significantly more frequent in the controls compared with PCOS women [16]. In contrast, in the present study we found an increased frequency of the IRS-1 variant in PCOS women, whereas the PPAR-γ exon 2 and exon 6 variants were similarly distributed in PCOS women and controls. Difference in ethnicity and clinical characteristics may account for disparities between these two studies.

Consistently with the studies above mentioned we found an effect of PPAR-γ polymorphisms on the weight of PCOS women, as carriers of the exon 6 variant were trendwise less likely to be overweight or obese compared with the wild type. Furthermore, IRS-1 and PPAR-γ exon 2 variants were associated with lower 17-β estradiol and free testosterone levels, respectively.

Concerning glucose metabolism, carriers of A allele at position 972 of the IRS-1 gene showed a tendency toward higher HOMA-IR, IGI and DI, whereas carriers of T allele at position 447 of the PPAR-γ exon 6 gene showed a borderline lower degree of insulin resistance, as demonstrated by lower HOMA-IR, higher Matsuda index, lower IGI and higher DI. Finally, carriers of G allele at position 12 of the PPAR-γ exon 2 gene showed lower HOMA-IR, significantly higher IGI and DI. These data are consistent with a protective or detrimental effect of PPAR-γ exon 2 and exon 6 or IRS-1 variants on insulin-resistance and beta-cell function. Certain allelic combinations may also modulate the degree of insulin resistance, as PCOS women heterozygous for IRS-1 and PPAR-γ exon 6, and wild type for PPAR-γ exon 2 showed higher Matsuda index values when compared with those heterozygous for IRS-1, wild type for PPAR-γ exon 2, and wild type for PPAR-γ exon 2 (P = 0.03). In this regard, Dasgupta [16] similarly found that PCOS women carrying both IRS-1 and PPAR-γ polymorphisms had a lower frequency of hyperandrogenic and metabolic derangements compared to the wild types, although measurements of insulin resistance and beta-cell function was not performed.

Strengths of our research include selection of a homogenous population and evaluation of both insulin resistance and insulin secretion indexes. Although glucose clamp still represents the gold standard for evaluation of insulin resistance, both HOMA-IR and Matsuda index are well-known proxy of insulin resistance and sensitivity, and show a good correlation with glucose clamp [25]. Furthermore, there is no gold standard method for evaluating insulin secretion, and it is well known that insulin secretion may depend on insulin resistance according to a hyperbolic rule, as defined by the DI. This study has, however, two main limitations: i) the limited sample size and the lack of statistical power sufficient to detect small difference between groups; ii) the absence of glucose clamp.

In conclusion, both PPAR-γ and IRS-1 polymorphisms, alone or combined in specific haplotypes, were associated with differences in hormonal and metabolic parameters in women with PCOS, thus confirming the protective influence of PPAR-γ exon 2 and exon 6 variants on insulin resistance and beta-cell function, and the detrimental effect of IRS-1 polymorphism. However, some of these associations were weak and do not fully explain the high metabolic risk associated with PCOS.

Declaration of interests

None.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.jcte.2018.05.002.
References

[1] ESHRE/ASRM Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.

[2] Legro RS, Kusnerman AR, Dodson WC, Dunia A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–69.

[3] Ovalle F, Aziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002;77:1095–105.

[4] Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010;95:2038–49.

[5] Ehrmann DA, Liljenquist DR, Kazsa K, Aziz R, Legro RS, Ghazzi MN, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48–53.

[6] Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223.

[7] Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998;138:269.

[8] Jones MR, Goodarzi MO. Genetic determinants of polycystic ovary syndrome: beta-cell function: a key pathological determinant in polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:310–5.

[9] Jones MR, Goodarzi MO. Genetic determinants of polycystic ovary syndrome: progress and future directions. Fertil Steril 2016;106:25–32.

[10] Pappalardo MA, Vita R, Di Bari F, Le Donne M, Trimarchi F, Benvenga S. Gly972Arg polymorphisms in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:310–5.

[11] Orio Jr F, Palomba S, Cascella T, Di Biase S, Labela L, Russo T, et al. Lack of an association between peroxisome proliferator-activated receptor-gamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:5110–5.

[12] San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 2004;89:2640–6.

[13] Xita N, Lazerou L, Georgiou I, Tsatsoulis A. The Pro12Ala polymorphism of the PPARgamma gene is not associated with the polycystic ovary syndrome. Hormones (Athens) 2009;8:267–72.

[14] Shaikh F, Janusen OS, Hahn S, Jacob S, Gleich J, Kotzka J, et al. Increased low grade inflammatory serum markers in patients with Polycystic ovary syndrome (PCOS) and their relationship to PPARgamma gene variants. Exp Clin Endocrinol Diabetes 2008;116:481–6.

[15] Bidzinska-Speichert B, Lenarcik A, Tworowska-Bardzinska U, Slezak R, Bednarek-Tupikowska G, Milewicz A, et al. Polymorphism in the PPAR gamma gene is not associated with polycystic ovary syndrome. Gynecol Endocrinol 2006;22:336–7.

[16] Tok EC, Aktas A, Erdal EM, Dilek S. Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-gamma2. Horm Res 2005;63:1590–5.

[17] Knebel B, Janssen OE, Hahn S, Jacob S, Gleich J, Kotzka J, et al. Increased low grade inflammatory serum markers in patients with Polycystic ovary syndrome (PCOS) and their relationship to PPARgamma gene variants. Exp Clin Endocrinol Diabetes 2008;116:481–6.

[18] Yilmaz M, Ergün MA, Karakoç A, Yurtçu E, Cakir N, Arslan M. Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:5887–92.

[19] Orlo Jr F, Palomba S, Cascella T, Di Biase S, Labela L, Russo T, et al. Lack of an association between peroxisome proliferator-activated receptor-gamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:5110–5.

[20] San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 2004;89:2640–6.

[21] Koika V, Marisoli DJ, Saltamavros AD, Vervia V, Koutogianni KD, Adonakis G, et al. Association of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma2 with decreased basic metabolic rate in women with polycystic ovary syndrome. Eur J Endocrinol 2009;161:317–22.

[22] Shaikh F, Janusen OS, Hahn S, Jacob S, Gleich J, Kotzka J, et al. Increased low grade inflammatory serum markers in patients with Polycystic ovary syndrome (PCOS) and their relationship to PPARgamma gene variants. Exp Clin Endocrinol Diabetes 2008;116:481–6.

[23] Bidzinska-Speichert B, Lenarcik A, Tworowska-Bardzinska U, Slezak R, Bednarek-Tupikowska G, Milewicz A, et al. Polymorphism in the PPAR gamma gene is not associated with polycystic ovary syndrome. Gynecol Endocrinol 2006;22:336–7.

[24] Tok EC, Aktas A, Erdal EM, Dilek S. Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-gamma2. Horm Res 2005;63:1590–5.

[25] Knebel B, Janssen OE, Hahn S, Jacob S, Gleich J, Kotzka J, et al. Increased low grade inflammatory serum markers in patients with Polycystic ovary syndrome (PCOS) and their relationship to PPARgamma gene variants. Exp Clin Endocrinol Diabetes 2008;116:481–6.

[26] Yilmaz M, Ergün MA, Karakoç A, Yurtçu E, Cakir N, Arslan M. Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:5887–92.

[27] Orlo Jr F, Palomba S, Cascella T, Di Biase S, Labela L, Russo T, et al. Lack of an association between peroxisome proliferator-activated receptor-gamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:5110–5.

[28] San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 2004;89:2640–6.

[29] Koika V, Marisoli DJ, Saltamavros AD, Vervia V, Koutogianni KD, Adonakis G, et al. Association of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma2 with decreased basic metabolic rate in women with polycystic ovary syndrome. Eur J Endocrinol 2009;161:317–22.

[30] Xita N, Lazerou L, Georgiou I, Tsatsoulis A. The Pro12Ala polymorphism of the PPARgamma gene is not associated with the polycystic ovary syndrome. Hormones (Athens) 2009;8:267–72.